MIRXES-B(02629.HK)預計5月23日上市 引入北京潯瑞及Evergreen Gate作爲基石
格隆匯5月15日丨MIRXES-B(02629.HK)發佈公告，公司擬全球發售4662萬股股份，中國香港發售股份466.2萬股，國際發售股份4195.8萬股；2025年5月15日至5月20日招股；發售價將爲每股發售股份23.30港元，每手買賣單位爲100股，中金公司及建銀國際爲聯席保薦人；預期股份將於2025年5月23日開始在聯交所買賣。
成立於2014年，集團是一家總部位於新加坡的微小核糖核酸(“miRNA”)技術公司，致力於使疾病篩查診斷解決方案在亞洲關鍵市場(包括新加坡及中國)觸手可及。截至最後實際可行日期，集團擁有一種核心產品(即GASTROClearTM)、兩種其他商業化產品(即LUNGClearTM及FortitudeTM)及六種處於臨牀前階段的候選產品。集團的核心產品GASTROClearTM爲一個由12種miRNA生物標誌物組成的用於胃癌篩查的基於血液的miRNA檢測組。GASTROClearTM已於2019年5 月獲得新加坡衛生科學局(“HSA”)的C類體外診斷(“IVD”)證書後在新加坡成功商業化。
集團已與北京潯瑞企業管理合夥企業(有限合夥)(“北京潯瑞”)及Evergreen Gate Limited(“Evergreen Gate”，爲復星財富國際控股有限公司的全資附屬公司，其由復星國際(00656.HK)間接全資擁有)(作爲集團的基石投資者)訂立基石投資協議，據此，各基石投資者已同意在若幹條件的規限下按發售價認購可以5792萬美元(或約4.49億港元)的總金額購買的若幹數目的發售股份。。
估計公司全球發售所得款項淨額合共(按發售價每股股份23.30港元計算)將約爲8.805億港元。其中，全球發售所得款項淨額的51.0%預計將主要用於集團核心產品GASTROClearTM的研發、監管備案以及生產及商業化；約24.0%將爲正在進行及計劃進行的研發提供資金，以進一步開發集團的管線產品；約15.0%將用於加強並整合集團的“端到端”能力，以把握價值鏈上的巨大商業潛力；及全球發售所得款項淨額的10.0%將用作集團的營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
